Added to YB: 2026-09-15
Pitch date: 2026-09-12
OTLK [neutral]
Outlook Therapeutics, Inc.
-2.45%
current return
Author Info
No bio for this author
Company Info
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.
Market Cap
$160.7M
Pitch Price
$0.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.02
P/E
-0.88
EV/Sales
-144.28
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 4 Session 2 - Outlook Therapeutics, Inc.
OTLK (quick overview): Outlook Therapeutics’ LYTENAVA, the first FDA-approved ophthalmic bevacizumab for wet AMD, could have greater strategic value inside an established retina platform than as a standalone launch. It addresses roughly 2.2M annual repackaged-bevacizumab injections, with pricing indicated at or below $500 per dose and a permanent J-code expected in April 2027. The key risk is practices sticking with cheaper repackaged bevacizumab, biosimilars or longer-acting brands.
Read full article (2 min)